208340 — PharmAbcine Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for PharmAbcine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	59.8	67.7	207	75	3,886
Cost of Revenue
Gross Profit	—	—	—	—	449
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	25,567	35,214	24,194	12,177	11,606
Operating Profit	-25,507	-35,146	-23,987	-12,102	-7,721
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-30,678	-44,033	-30,548	-14,247	-4,924
Provision for Income Taxes
Net Income After Taxes	-30,678	-44,033	-30,548	-14,247	-4,924
Net Income Before Extraordinary Items
Net Income	-30,678	-44,033	-30,548	-14,247	-4,924
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-30,678	-44,033	-30,548	-14,247	-4,924
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1,520	-2,274	-1,162	-550	-93.1
Dividends per Share